NCT04074889 & - Bifidobacterium bifidum BCMC TM 02290 + Bifidobacterium longum BCMC 02120 + Bifidobacterium longum infantis BCMC 02129 + Lacticaseibacillus casei BCMC 12313 + Lactobacillus acidophilus BCMC 12130 + Lactobacillus delbrueckii lactis BCMC 12451 & Non-Alcoholic Fatty Liver Disease (NAFLD) / Metabolic dysfunction-associated fatty liver disease (MAFLD)

Background

Non-alcoholic fatty liver disease (NAFLD) is currently treated through lifestyle changes, which include adopting a low-fat diet, losing weight, and engaging in regular exercise. The gut microbiota is an integral component of the gut–liver axis and presents a promising target for the treatment of NAFLD (1).

Study overview

It is a randomized, double-blind, placebo-controlled treatment trial studying Bifidobacterium bifidum BCMC 02290 + Bifidobacterium longum BCMC 02120+ Bifidobacterium longum infantis BCMC 02129 + Lacticaseibacillus casei BCMC 12313 + Lactobacillus acidophilus BCMC 12130 + La…